Key Highlights
- ADAR1 Capital Management acquired roughly $117,700 in InMed Pharmaceuticals common stock through open-market transactions.
- The buying expands its indirect holding to 892,101 shares.
- The shares are held under Daniel Schneeberger's beneficial ownership via managed funds.
- Executions were completed at average prices of about $1.29 per share.
InMed Pharmaceuticals Inc. (NASDAQ: INM) saw ADAR1 Capital Management acquire roughly $117,700 in common stock through open-market transactions.
Company Overview
InMed Pharmaceuticals is a biopharmaceutical company focused on developing cannabinoid-based drug candidates for a range of therapeutic indications. The company has built a synthetic biology Manufacturing platform, IntegraSyn, designed to produce rare cannabinoids at commercial scale without relying on plant-based extraction, an approach intended to provide more consistent and scalable drug Supply than traditional cannabis cultivation methods.
InMed has applied its cannabinoid-focused pipeline and manufacturing capabilities across both pharmaceutical Drug Development and other commercial applications, positioning the company's synthetic biology platform as a potential differentiator relative to other cannabinoid-focused drug developers reliant on plant extraction or chemical synthesis methods that can be more difficult to scale consistently.
What Happened
The buying expands ADAR1 Capital Management's indirect holding to 892,101 shares under Daniel Schneeberger's beneficial ownership via managed funds, with executions completed at average prices of about $1.29 per share.
Market Reaction
Insider or major Shareholder purchases of this kind are often viewed by investors as a signal of confidence in a company's prospects, though the disclosed information does not include additional context on the specific rationale behind this particular purchase.
Outlook
The disclosed information does not include specific forward guidance beyond this stock purchase; investors are likely to watch for further disclosures on InMed's cannabinoid pipeline and IntegraSyn manufacturing platform progress.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...